Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 6 · 75%Moderate 0 · 0%High 0 · 0%

Regdanvimab vs placebo

Mortality by day 30Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low

Regdanvimab vs placebo

Mortality by day 60Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regdanvimab vs placebo

Clinical progression: development of severe symptoms (≥ 7 WHO scale, IMV) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low

Regdanvimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regdanvimab vs placebo

Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Regdanvimab showed no clear difference in admission to hospital or death by day 30Â compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.45 [0.14, 1.42]
1 study · 204 participants
Low

Regdanvimab vs placebo

Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Regdanvimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.96 [0.64, 1.43]
1 study · 215 participants
Low

Regdanvimab vs placebo

Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Regdanvimab showed no clear difference in adverse events: grades 3 and 4 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 2.62 [0.52, 13.12]
1 study · 215 participants
Low

Regdanvimab vs placebo

Serious adverse events by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low